Published in Regul Pept on January 15, 2005
Intestinal mucosal atrophy and adaptation. World J Gastroenterol (2012) 1.06
GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes (2012) 1.03
Intestinal hormones and growth factors: effects on the small intestine. World J Gastroenterol (2009) 0.98
Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats. JPEN J Parenter Enteral Nutr (2008) 0.98
Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract (2009) 0.97
Early but not late administration of glucagon-like peptide-2 following ileo-cecal resection augments putative intestinal stem cell expansion. Am J Physiol Gastrointest Liver Physiol (2008) 0.96
Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol (2006) 0.94
Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg (2010) 0.93
Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats. Am J Physiol Regul Integr Comp Physiol (2008) 0.92
Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells. Cancer Res (2008) 0.92
Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology (2012) 0.90
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis. Nat Rev Gastroenterol Hepatol (2012) 0.87
Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology (2010) 0.87
Axon-like basal processes in enteroendocrine cells: characteristics and potential targets. Clin Transl Sci (2011) 0.86
Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver Physiol (2009) 0.85
Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice. Endocrinology (2012) 0.85
Teduglutide, a novel glucagon-like peptide 2 analog, in the treatment of patients with short bowel syndrome. Therap Adv Gastroenterol (2012) 0.83
Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway. Am J Physiol Endocrinol Metab (2010) 0.83
Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-γ signaling. Am J Physiol Endocrinol Metab (2012) 0.82
Animal models of gastrointestinal and liver diseases. Animal models of infant short bowel syndrome: translational relevance and challenges. Am J Physiol Gastrointest Liver Physiol (2014) 0.81
The role of growth factors in intestinal regeneration and repair in necrotizing enterocolitis. Semin Pediatr Surg (2013) 0.78
The Pathogenesis of Resection-Associated Intestinal Adaptation. Cell Mol Gastroenterol Hepatol (2016) 0.78
IGF binding protein-4 is required for the growth effects of glucagon-like peptide-2 in murine intestine. Endocrinology (2014) 0.77
The intestinotrophic peptide, GLP-2, counteracts the gastrointestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, erlotinib, and cisplatin. Dig Dis Sci (2010) 0.76
The effect of glucagon-like Peptide-2 receptor agonists on colonic anastomotic wound healing. Gastroenterol Res Pract (2010) 0.76
Emerging treatment options for short bowel syndrome: potential role of teduglutide. Clin Exp Gastroenterol (2011) 0.76
Glucagon-like peptide-2 (GLP-2) increases net amino acid utilization by the portal-drained viscera of ruminating calves. Animal (2012) 0.75
Glucagon-like peptide-2 protects impaired intestinal mucosal barriers in obstructive jaundice rats. World J Gastroenterol (2015) 0.75
Interdependency of EGF and GLP-2 Signaling in Attenuating Mucosal Atrophy in a Mouse Model of Parenteral Nutrition. Cell Mol Gastroenterol Hepatol (2017) 0.75
The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Mol Metab (2017) 0.75
Effects of exogenous glucagon-like peptide-2 and distal bowel resection on intestinal and systemic adaptive responses in rats. PLoS One (2017) 0.75
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet (2002) 4.29
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med (2002) 3.55
Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis (2007) 3.01
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J (2011) 2.32
Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. Am J Clin Nutr (2005) 2.25
GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology (2013) 1.89
GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept (2003) 1.70
Corneal endothelial cell changes after cataract surgery in patients on systemic sympathetic α-1a antagonist medication (tamsulosin). Acta Ophthalmol (2013) 1.58
Effects of everyday life events on glucose, insulin, and glucagon dynamics in continuous subcutaneous insulin infusion-treated type 1 diabetes: collection of clinical data for glucose modeling. Diabetes Technol Ther (2011) 1.55
Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 1.52
Somatostatin receptors. Biochim Biophys Acta (2003) 1.49
Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab (2006) 1.49
Bacterial biofilm formation and treatment in soft tissue fillers. Pathog Dis (2014) 1.44
Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul Pept (2004) 1.35
GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology (2003) 1.31
Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol (2009) 1.31
GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab (2008) 1.22
Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care (2011) 1.22
Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol (2010) 1.18
Effects of free fatty acids per se on glucose production, gluconeogenesis, and glycogenolysis. Diabetes (2003) 1.17
Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes (2010) 1.16
Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes (2005) 1.16
IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol (2008) 1.14
Effect of dairy calcium or supplementary calcium intake on postprandial fat metabolism, appetite, and subsequent energy intake. Am J Clin Nutr (2007) 1.11
Early differential defects of insulin secretion and action in 19-year-old caucasian men who had low birth weight. Diabetes (2002) 1.10
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol (2007) 1.10
Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res (2006) 1.09
Erratum. Evidence of Extrapancreatic Glucagon Secretion in Man. Diabetes 2016;65:585-597. Diabetes (2016) 1.09
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans. Am J Physiol Endocrinol Metab (2009) 1.06
Circulating leptin and thyroid dysfunction. Eur J Endocrinol (2003) 1.05
In vivo biology and toxicology of fullerenes and their derivatives. Basic Clin Pharmacol Toxicol (2008) 1.05
Acute effects of ghrelin administration on glucose and lipid metabolism. J Clin Endocrinol Metab (2007) 1.05
Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes (2006) 1.04
Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol (2014) 1.03
Onset of small intestinal atrophy is associated with reduced intestinal blood flow in TPN-fed neonatal piglets. J Nutr (2004) 1.01
Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone (2006) 1.01
Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care (2013) 1.00
Enteral feeding without pancreatic stimulation. Pancreas (2005) 1.00
The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol (2013) 1.00
Automated detection of hypoglycemia-induced EEG changes recorded by subcutaneous electrodes in subjects with type 1 diabetes--the brain as a biosensor. Diabetes Res Clin Pract (2010) 0.99
Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. Int Immunopharmacol (2006) 0.99
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia (2014) 0.98
Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept (2005) 0.97
Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology (2003) 0.97
Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. Am J Physiol Gastrointest Liver Physiol (2014) 0.97
Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice. Regul Pept (2012) 0.97
The effects of L-arabinose on intestinal sucrase activity: dose-response studies in vitro and in humans. Am J Clin Nutr (2011) 0.96
Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone (2004) 0.94
The L-α-amino acid receptor GPRC6A is expressed in the islets of Langerhans but is not involved in L-arginine-induced insulin release. Amino Acids (2012) 0.93
Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol (2006) 0.93
Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab (2007) 0.93
Corneal endothelial morphology and central thickness in patients with type II diabetes mellitus. Acta Ophthalmol (2013) 0.92
Effect of viscosity on appetite and gastro-intestinal hormones. Physiol Behav (2009) 0.92
Sensing of triacylglycerol in the gut: different mechanisms for fatty acids and 2-monoacylglycerol. J Physiol (2015) 0.91
Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol (2009) 0.91
TH17 cell induction and effects of IL-17A and IL-17F blockade in experimental colitis. Inflamm Bowel Dis (2013) 0.91
The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept (2002) 0.91
Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept (2005) 0.90
Dexamethasone/1alpha-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model. Immunology (2008) 0.90
Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem (2002) 0.90
Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab (2013) 0.90
Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab (2014) 0.89
Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis. Clin Gastroenterol Hepatol (2008) 0.89
Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Metabolism (2009) 0.89
Exendin-4, but not dipeptidyl peptidase IV inhibition, increases small intestinal mass in GK rats. Am J Physiol Gastrointest Liver Physiol (2007) 0.88
Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome. Scand J Gastroenterol (2008) 0.88
Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. J Cereb Blood Flow Metab (2012) 0.88
An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology (2014) 0.88
Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros (2012) 0.87
Glutamate prevents intestinal atrophy via luminal nutrient sensing in a mouse model of total parenteral nutrition. FASEB J (2014) 0.87
The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept (2011) 0.86
Corneal endothelial cell changes associated with cataract surgery in patients with type 2 diabetes mellitus. Cornea (2011) 0.85
Differential postprandial lipoprotein responses in type 2 diabetic men with and without clinical evidence of a former myocardial infarction. Rev Diabet Stud (2005) 0.85
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib. Clin Cancer Res (2007) 0.85
Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight. J Clin Endocrinol Metab (2005) 0.85
Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis (2010) 0.84
Changes of cognition and regional cerebral activity during acute hypoglycemia in normal subjects: A H2 15O positron emission tomographic study. J Neurosci Res (2009) 0.84
Treatment of adult short bowel syndrome patients with teduglutide. Expert Opin Pharmacother (2012) 0.84
Expression of the epidermal growth factor system in eutopic endometrium from women with endometriosis differs from that in endometrium from healthy women. Gynecol Obstet Invest (2008) 0.84
Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads. Am J Physiol Gastrointest Liver Physiol (2005) 0.84
Continuous parenteral and enteral nutrition induces metabolic dysfunction in neonatal pigs. JPEN J Parenter Enteral Nutr (2012) 0.84
Introduction of enteral food increases plasma GLP-2 and decreases GLP-2 receptor mRNA abundance during pig development. J Nutr (2003) 0.84
Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats. Regul Pept (2002) 0.83
No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects. Clin Endocrinol (Oxf) (2008) 0.83